Aurobindo Pharma Stock Screener | Share Price & Fundamental Analysis
AUROPHARMA
Pharmaceuticals
Share Price NSE
₹1158.80
▼
-12.60 (-1.08%)
Share Price BSE
₹1159.75
▼
-16.00 (-1.36%)
Track Aurobindo Pharma share price live with TickJournal's free stock screener.
Analyze Aurobindo Pharma share price history trends and compare 52-week high low
levels.
Calculate AUROPHARMA stock fair value using fundamental analysis and view live share price charts.
Determine Aurobindo Pharma share intrinsic value and compare it with current AUROPHARMA share price.
Record your Aurobindo Pharma trades in TickJournal's free trading journal and track your portfolio performance.
Aurobindo Pharma Market Cap
₹68,801.76 Cr.
EPS (TTM)
₹59.81
Dividend Yield
-
Debt to Equity
0.24
AUROPHARMA 52 Week High
₹1257.80
Aurobindo Pharma 52 Week Low
₹1025.00
Operating Margin
21.00%
Profit Margin
10.60%
AUROPHARMA Revenue (TTM)
₹8,516.00
EBITDA
₹1,894.00
Net Income
₹903.00
Total Assets
₹49,785.00
Total Equity
₹32,647.00
Aurobindo Pharma Share Price History - Stock Screener Chart
Screen AUROPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Aurobindo Pharma Company Profile - Fundamental Screener
Screen Aurobindo Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AUROPHARMA shares.
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
M R Kumar
ISIN
INE406A01037
Website
https://www.aurobindo.com
Aurobindo Pharma Balance Sheet Screener
Screen AUROPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 49,785 | 45,072 | 39,890 | 33,922 | 33,854 | 28,928 | 26,454 | 21,101 | 16,249 | 15,920 |
| Current Assets | 27,163 | 23,772 | 21,460 | 18,123 | 19,824 | 16,413 | 15,332 | 12,178 | 9,206 | 10,294 |
| Fixed Assets | 14,794 | 14,493 | 11,024 | 10,532 | 9,374 | 9,397 | 8,475 | 6,521 | 4,834 | 4,180 |
| Liabilities | ||||||||||
| Total Liabilities | 49,785 | 45,072 | 39,890 | 33,922 | 33,854 | 28,928 | 26,454 | 21,101 | 16,249 | 15,920 |
| Current Liabilities | 2,456 | 3,022 | 1,544 | 1,192 | 1,260 | 718 | 541 | 753 | 270 | 790 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 32,647 | 29,851 | 26,852 | 24,574 | 21,929 | 16,825 | 13,892 | 11,682 | 9,374 | 7,290 |
| Share Capital | 58 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves & Surplus | 32,595 | 29,784 | 26,781 | 24,517 | 21,871 | 16,766 | 13,832 | 11,622 | 9,313 | 7,229 |
Aurobindo Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Aurobindo Pharma income statement and profit fundamentals.
Analyze AUROPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aurobindo Pharma share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,516 | 7,899 | 8,359 | 8,793 | 7,628 | 7,679 | 7,783 | 8,052 | 6,514 | 6,907 | 7,339 | 7,434 | 5,844 | 6,218 | 5,731 |
| Expenses | 6,622 | 6,265 | 6,608 | 6,938 | 6,042 | 5,949 | 6,230 | 6,401 | 5,477 | 5,772 | 5,846 | 5,753 | 5,002 | 5,303 | 4,950 |
| EBITDA | 1,894 | 1,634 | 1,752 | 1,855 | 1,585 | 1,730 | 1,553 | 1,652 | 1,037 | 1,135 | 1,493 | 1,681 | 842 | 914 | 781 |
| Operating Profit % | 21.00% | 20.00% | 20.00% | 19.00% | 19.00% | 20.00% | 19.00% | 19.00% | 14.00% | 15.00% | 18.00% | 21.00% | 14.00% | 14.00% | 13.00% |
| Depreciation | 444 | 406 | 429 | 465 | 354 | 404 | 382 | 419 | 346 | 327 | 418 | 423 | 254 | 280 | 298 |
| Interest | 115 | 98 | 95 | 93 | 89 | 111 | 113 | 119 | 56 | 57 | 68 | 76 | 9 | 15 | 25 |
| Profit Before Tax | 1,335 | 1,207 | 1,276 | 1,339 | 1,230 | 1,324 | 1,208 | 1,200 | 730 | 812 | 1,076 | 1,262 | 594 | 679 | 523 |
| Tax | 432 | 383 | 428 | 429 | 323 | 406 | 391 | 354 | 224 | 242 | 324 | 323 | 18 | 159 | 113 |
| Net Profit | 903 | 824 | 848 | 910 | 907 | 918 | 817 | 846 | 506 | 570 | 752 | 940 | 576 | 520 | 410 |
| EPS | 15.56 | 14.20 | 14.61 | 15.67 | 15.51 | 15.69 | 14.00 | 14.56 | 8.64 | 9.74 | 12.83 | 16.04 | 9.84 | 8.88 | 6.99 |
Aurobindo Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AUROPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,925 | 2,435 | 2,387 | 5,017 | 3,329 | 4,381 | 1,651 | 1,955 | 3,279 | 1,420 |
| Investing Activities | -1,866 | -4,242 | -3,971 | -3,211 | 597 | -1,563 | -2,904 | -1,927 | -1,787 | -1,446 |
| Financing Activities | 120 | 800 | 1,814 | -2,969 | -1,365 | -1,947 | 1,919 | 864 | -1,915 | 365 |
| Net Cash Flow | 2,178 | -1,007 | 230 | -1,164 | 2,561 | 871 | 666 | 892 | -424 | 340 |
Aurobindo Pharma Shareholding Pattern Screener
See Aurobindo Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Aurobindo Pharma promoter holding and ownership changes for AUROPHARMA on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.82% | 51.82% | 51.82% | 51.82% | 51.83% | 51.80% | 51.82% | 51.82% |
| FII Holding | 15.33% | 14.37% | 14.21% | 13.94% | 18.02% | 16.73% | 16.59% | 16.29% |
| DII Holding | 26.23% | 26.93% | 27.60% | 27.68% | 23.28% | 24.77% | 25.13% | 25.20% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.47% | 5.67% | 5.25% | 5.36% | 5.52% | 5.47% | 5.33% | 5.52% |
| Other Holding | 1.15% | 1.20% | 1.13% | 1.19% | 1.36% | 1.23% | 1.13% | 1.17% |
| Shareholder Count | 269,323 | 272,208 | 247,662 | 236,859 | 244,575 | 238,622 | 248,488 | 257,962 |
Aurobindo Pharma Share Dividend Screener - Share Yield Analysis
Check Aurobindo Pharma dividend history with payout and yield data.
View Aurobindo Pharma dividend details including ex-dates and amounts for AUROPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹4.50 | 0.39% |
| 2023-March | ₹7.50 | 0.69% |
| 2022-March | ₹9.00 | 1.77% |
| 2021-March | ₹4.00 | 0.60% |
| 2020-March | ₹3.00 | 0.34% |
| 2019-March | ₹2.50 | 0.61% |
| 2018-March | ₹2.50 | 0.32% |
| 2017-March | ₹3.20 | 0.57% |
Aurobindo Pharma Stock Index Membership
See which indices include Aurobindo Pharma stock.
Check AUROPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Aurobindo Pharma Market Events Screener - Corporate Actions
Get Aurobindo Pharma corporate actions including splits, bonuses, and buybacks.
Check Aurobindo Pharma stock events that may affect AUROPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -0.84% | ||
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 3.52% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 4.74% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 4.00 /share | -0.94% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -1.96% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -1.63% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 3.04% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -4.90% |
| 2024-08-29 | 2024-08-29 | Annual General Meeting | NA | 11.38% |
| 2024-07-30 | 2024-08-05 | Buyback | 1460 | -2.41% |
| 2024-02-20 | 2024-02-20 | Dividend | ₹ 1.50 /share | 3.84% |
| 2023-11-20 | 2023-11-20 | Dividend | ₹ 3.00 /share | 7.58% |
| 2023-02-17 | 2023-02-17 | Dividend | ₹ 3.00 /share | 7.83% |
| 2022-06-06 | 2022-06-07 | Dividend | ₹ 4.50 /share | -1.36% |
| 2022-02-18 | 2022-02-21 | Dividend | ₹ 1.50 /share | 1.04% |
Aurobindo Pharma Competitors Screener - Peer Comparison
Screen AUROPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 408,007 | 37.20 | 54,729 | 9.71% | 10,980 | 53.25 |
| Divis Laboratories | 163,250 | 66.07 | 9,712 | 18.67% | 2,191 | 48.15 |
| Torrent Pharmaceuticals | 144,229 | 64.43 | 11,539 | 6.99% | 1,911 | 70.35 |
| Cipla | 109,566 | 23.71 | 28,410 | 7.12% | 5,291 | 45.95 |
| Dr Reddys Laboratories | 105,948 | 19.16 | 33,741 | 16.73% | 5,725 | 58.53 |
| Lupin | 101,478 | 21.52 | 22,910 | 13.74% | 3,306 | 60.82 |
| Zydus Life Science | 91,613 | 18.12 | 23,511 | 18.55% | 4,615 | 52.96 |
| Mankind Pharma | 86,000 | 47.17 | 12,744 | 20.90% | 2,007 | 45.43 |
| Aurobindo Pharma | 68,802 | 19.14 | 32,346 | 9.43% | 3,484 | 51.95 |
| Alkem Laboratories | 65,528 | 26.80 | 13,458 | 3.70% | 2,216 | 40.44 |
Aurobindo Pharma Company Announcements - News Screener
Screen AUROPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View | |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-16 | Completion Of US FDA Inspection At Unit-VII Of Aurobindo Pharma Limited Jedcherla | View |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Restructuring | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-15 | Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-02-15 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2026-02-12 | Completion Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd. A Wholly Owned Subsidiary Of The Company | View |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-02 | Clarification On Significant Volume Movement In CompanyS Shares | View |
| 2026-02-01 | Clarification sought from Aurobindo Pharma Ltd | - |
| 2026-01-31 | Clarification On Significant Volume Movement In CompanyS Shares | View |